NCT01605890 - Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

HIV-2 Infection

Interventions

DRUG

emtricitabine / tenofovir disoproxil fumarate / raltegravir .

"emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.~raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID."

Trial Locations (1)

75018

Hôpital Bichat-Claude Bernard, Paris